Key points from article :
Bonerge has launched a 108-person clinical trial to explore the anti-ageing potential of three key compounds: Fisetin, Urolithin A, and Ergothioneine. This trial focuses on assessing their effects on skin health and organ rejuvenation, targeting key indicators such as skin elasticity, wrinkles, inflammation, and tone over a 56-day period, corresponding to two skin regeneration cycles. By examining both individual and combined effects of these compounds, the study aims to uncover new strategies for combating visible and systemic ageing.
Senolytics, a field dedicated to removing ageing-related senescent cells, has shown promise in anti-ageing research. Recent findings, such as the Mayo Clinic’s identification of the IL-23R biomarker and Fisetin’s senescent cell-clearing properties, suggest potential for organ rejuvenation. Bonerge’s trial builds on this foundation, with Fisetin targeting inflammation and ageing cells, Urolithin A addressing photoaging and oxidative stress, and Ergothioneine protecting mitochondria to reduce cellular damage. Together, these compounds may offer a synergistic approach to skin and overall health.
Set to conclude in March 2025, the trial holds promise for advancing Senolytics from research to practical applications. Bonerge aims to provide strong evidence for using these compounds in anti-ageing treatments, potentially transforming skin health and offering broader benefits for combating ageing at the organ and systemic levels.
